PUBLIC COMPANY
saveUniquity Bio Inc
updated 3mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Novo revamps its direct-to-consumer platform; Roche drug Gazyva approved againPlus news about Uniquity Bio, Commit Biologics, Rosemont Pharmaceuticals, Aytu and Aclaris Therapeutics. Novo relaunches NovoCare direct-to-consumer platform: Novo is revamping its DTC business wit…endpoints · 4d ago
- Aclaris drops TSLP program from pipeline after flunking phase 2 eczema testA phase 2 study of Aclaris Therapeutics’ bosakitug in atopic dermatitis has missed its primary endpoint, adding to the setbacks anti-TSLP antibodies have encountered in the indication.fiercebiotech · 5d ago
- Sanofi-backed Windward hits $225M IPO goal, as Rezera delays listing over ‘market conditions’Windward Bio’s IPO has blown to exactly the spot the Swiss biotech had been aiming for, bringing in $225 million to fund a pair of respiratory drugs licensed from China.fiercebiotech · 8d ago
- Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from ChinaWindward Bio is sailing toward the public markets with the aim of raising over $200 million in proceeds to fund two respiratory drugs licensed from China.fiercebiotech · 12d ago
comments(0)
5-min edit window · permanent after that